New interchangeable copy of eye drug Lucentis wins approval
Published
The FDA approved Lucamzi, an interchangeable biosimilar of Lucentis, for wet macular degeneration, diabetic eye disease and other retinal conditions. Biosimilars often cost less than the original. It isn't expected in U.S. clinics until 2027.
Source: Eyes On Eyecare
This is a plain-language summary. Read the original source for full details.